Podcast Q&A: EU HTA Joint Clinical Assessments
In this episode of tHEORetically Speaking, join Dr. Rosemary Jose, Dr. Sonja Kroep, and Nick Halfpenny from OPEN Health, Dr. Ansgar Hebborn from Roche, and James Ryan from AstraZeneca, who answer questions from a recent webinar on several policy aspects regarding the current challenges and implications of the EU Health Technology Assessment (HTA) regulation.
Podcast Q&A: Cell & Gene Therapies
In this episode of tHEORetically Speaking, join Dr. Pamela Landsman-Blumberg, Amanda O’Hora, and Ajay Keshava from Magnolia Market Access, who answer questions from a recent webinar on how early stage planning taking into account commercial production, logistics, reimbursement, and health inequities can lead to successful approvals and market adoption.
Podcast Q&A: Patient-Centered Real-World Evidence in Rare Diseases
In this episode of tHEORetically Speaking, join Drs. Megan Gower and Edward Chou from Takeda, and Richard Tsai, MS from Inspire, who answer questions from a recent webinar on the challenges and solutions for generating patient-centered real-world evidence (RWE) in the context of rare diseases, to support clinical development through commercial post-approval.
Podcast Q&A: Real-World Evidence Generation with Disease Registries
In this episode of tHEORetically Speaking, join Drs. Javier Cid, Nahila Justo, and Delphine Saragoussi from Evidera and PPD, who answer questions from a recent webinar on why strong connections with registry groups and stakeholder populations are important for generating relevant real-world evidence to advance treatments.
Podcast Q&A: Clinical Outcome Assessment (COA) Translations
In this episode of tHEORetically Speaking, join Christelle Giroudet, MA and Ana Alvarez, MA, COA Linguistic Validation Leaders with ICON, as they highlight the importance of Linguistic Validation and how equivalence should be a key focus during the development of Clinical Outcome Assessment translations.
Patient Voices Matter: Transforming Industry-Sponsored Real-World Evidence with Patient-Centric Approaches
In this webinar, panelists address integrating patient-centered research into real-world studies, focusing on diversity, equity, and inclusion (DEI), and developing systemic approaches for a more equitable research ecosystem.
Strategies to Optimize Commercialization of Oncology Treatments for Younger Adults
Watch this webinar on addressing early onset cancer through strategic trial design, targeted launch indications, and increased trial access to speed up the delivery of impactful treatments.
How AI Can Help Dermatology: Diagnosis, Treatment, Risk, and R&D
The hype around AI is finally translating into real-world value, and we are seeing broader adoption of real-world data in Dermatology. This episode of tHEORetically Speaking features Dr. Stefan Weiss, Managing Director of Dermatology and Dr. Joseph Zabinski, Managing Director of AI and Personalized Medicine at OM1, who discuss the path to personalized medicine and AI-powered clinical decision support in dermatology.
The Future of Diversity in Clinical Trials: Real-World Evidence
This episode of tHEORetically Speaking features real-world evidence experts Alexandrina Balanean, Parisa Asgarisabet, and Danielle Gentile from Cardinal Health discussing the problems caused by lack of diverse representation in clinical trials.
EU HTA Joint Clinical Assessments: Navigating Potential Challenges Ahead of 2025
This panel discusses several policy aspects regarding the current challenges and implications of the EU Health Technology Assessment (HTA) regulation.
Cell & Gene Therapies – Beginning with the End in Mind
This webinar discusses how early stage planning taking into account commercial production, logistics, reimbursement, and health inequities can lead to successful approvals and market adoption.
Bridging the Gap: Strategies for Patient-Centered Real-World Evidence in Rare Diseases
Watch this webinar exploring real challenges and solutions for generating patient-centered real-world evidence (RWE) in the context of rare diseases to support clinical development through commercial post-approval.
Minimizing the Impact of Cross-Cultural Differences in COA Translations
ICON's COA Linguistic Validation Leaders highlight the importance of Linguistic Validation and how equivalence should be a key focus during the development of Clinical Outcome Assessment translations.
Partnering with Disease Registries: The Value and Impact for Real-World Evidence Generation
In this webinar, Evidera experts present guidance on why strong connections with registry groups and stakeholder populations are important for generating relevant real-world evidence to advance treatments.
Cracking the Code: When and How to Validate ICD Algorithms for RWE
Experts from SickKids, Genentech, Penn Medicine, and PHAR deliver a high level overview on validation of code algorithms for Real World Evidence (RWE)
Optimizing Real-World Evidence for Maternal and Neonatal Outcomes
Experts from health system innovators (C-Path), patients (PreemieWorld), healthcare payers (Carelon Research (formerly HealthCore) & Elevance Health (formerly Anthem)), and industry (Bayer) provide insights into improving neonatal outcomes using RWE.
How Literature Review Automation and Efficient Processes Streamline RWE HEOR Studies
Literature reviews are an essential element in Real World Evidence (RWE) HEOR studies that impact patient care, policy development, and healthcare decision making.
What Every Researcher Needs to Know About Using Medicare Data for Real World Evidence
Join three panelists who provide a practical overview of how and why to use data from Medicare for real world studies.
European Council for Cardiovascular Research
The history of the European Council for Cardiovascular Research (ECCR) goes back more than 30 years when the ‘European Blood Pressure Group’ held its [...]
Cutting Edge Conversations: Addressing Orphan and Rare Diseases
Joseph Zabinski, PhD, MEM, and Jonathan Kish, PhD, MPH, discuss how research groups are working in the realm of orphan and rare diseases.
Using External Control Arm Studies in HTA Submissions: An Alternative, When RCTs are not Feasible
Matthias Hunger, Céline Taveau, and Ankit Pahwa present the challenges and opportunities when using external control arm studies in submissions to HTA agencies.
Overcoming Clinical Research Challenges: Analyzing EHR Data to Replicate Clinical Trials and Construct External Control Arms
Mac Bonafede, Stella Chang, and Dr. Rajesh Dash provide an overview on defeating common clinical trial barriers by combining EHR data with advanced analytics technologies.
Marketplaces Drive Faster Science: HEOR, RWE & Market Access Sourcing
Join experts for an overview of the Scientist.com Marketplace for value, evidence, and access and a discussion on how it can increase efficiency in outsourced research projects to achieve "faster science".
